A Fermentation Strategy for Anti-MUC1 C595 Diabody Expression in Recombinant Escherichia Coli |
Lan, John Chi-Wei
(Biochemical Recovery Group, Department of Chemical Engineering, School of Engineering, University of Birmingham)
Ling, Tau Chuan (Biochemical Recovery Group, Department of Chemical Engineering, School of Engineering, University of Birmingham) Hamilton, Grant (Biochemical Recovery Group, Department of Chemical Engineering, School of Engineering, University of Birmingham) Lyddiatt, Andrew (Biochemical Recovery Group, Department of Chemical Engineering, School of Engineering, University of Birmingham) |
1 | Gendler, S. J., C. A. Lancaster, J. Taylor-Papadimitriou, T. Duhig, N. Peat, J. Burchell, L. Pemberton, E. N. Lalani, and D. Wilson (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265: 15286-15293 |
2 | Zhang, Z. R., D. A. O'Sullivan, and A. Lyddiatt (1999) Magnetically stabilised fluidised bed adsorption: practical benefit of uncoupling bed expansion from fluid velocities in the purification of a recombinant protein from Escherichia coli. J. Chem. Technol. Biotechnol. 74: 270-274 DOI ScienceOn |
3 | Farid, S. S. (2006) Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B In press |
4 | Lan, J. C., T. C. Ling, G. Hamilton, and A. Lyddiatt (2006) Production of an anti-MUC1 C595 dbFv antibody fragment in recombinant Escherichia coli. Process Biochem. In press |
5 | Meyer, H.-R., C. Leist, and A. Fiechter (1984) Acetate formation in continuous culture of Escherichia coli K12 D1 on defined and complex media. J. Biotechnol. 1: 355-358 DOI ScienceOn |
6 | Bostrom, M., K. Markland, A. M. Sanden, M. Hedhammar, S. Hober, and G. Larsson (2005) Effect of substrate feed rate on recombinant protein secretion, degradation and inclusion body formation in Escherichia coli. Appl. Microbiol. Biotechnol. 68: 82-90 DOI |
7 | Perkins, A. C, I. M. Symonds, M. V. Pimm, M. R. Price, M. L. Wastie, and E. M. Symonds (1993) Immunoscinti-graphy of ovarian carcinoma using a monoclonal antibody (111In-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope. Nucl. Med. Commun. 14: 578-586 DOI |
8 | Riesenberg, D., K. Menzel, V. Schulz, K. Schumann, G. Veith, G. Zuber, and W. A. Knorre (1990) High cell density fermentation of recombinant Escherichia coli expressing human interferon alpha 1. Appl. Microbiol. Biotechnol. 34: 77-82 |
9 | Croce, M. V, M. T. Isla-Larrain, S. O. Demichelis, J. R. Gori, M. R. Price, and A. Segal-Eiras (2003) Tissue and serum MUC1 mucin detection in breast cancer patients. Breast. Cancer Res. Treat. 81: 195-207 DOI ScienceOn |
10 | Denton, G., K. Brady, B. K. Lo, A. Murray, C. R. Graves, O. D. Hughes, S. J. Tendler, C. A. Laughton, and M. R. Price (1999) Production and characterization of an anti-(MUC1 mucin) recombinant diabody. Cancer Immunol Immunother. 48: 29-38 DOI |
11 | Berruti, A., M. Tampellini, M. Torta, T. Buniva, G. Gor-zegno, and L. Dogliotti (1994) Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur. J. Cancer 30A: 2082-2084 |
12 | Martoni, A., C. Zamagni, B. Bellanova, L. Zanichelli, F. Vecchi, N. Cacciari, E. Strocchi, and F. Pannuti (1995) CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur. J. Cancer 31A: 1615-1621 |
13 | Price, M. R., S. Briggs, M. J. Scanlon, S. J. B. Tendler, P. E. Sibley, and C. W. Hand (1991) The mucin antigens: what are we measuring? Dis. Markers 9: 205-212 |
14 | Seo, J. H. and J. E. Bailey (1985) Effects of recombinant plasmid content on growth properties and cloned gene product formation in Escherichia coli. Biotechnol. Bioeng. 27: 1668-1674 DOI ScienceOn |
15 | Petrakou, E., A. Murray, C. Rosamund, L. Graves, and M. R. Price (1998) Evaluation of Pepscan analyses for epitope mapping of anti-MUC1 monoclonal antibodies--a comparative study and review of five antibodies. Anticancer. Res. 18:4419-4421 |
16 | Shiloach, J. and R. Fass (2005) Growing E. coli to high cell density A historical perspective on method development. Biotechnol. Adv. 23: 345-357 DOI ScienceOn |
17 | Eiteman, M. A. and E. Altman (2006) Overcoming acetate in Escherichia coli recombinant protein fermentations. Trends Biotechnol. 24: 530-536 DOI ScienceOn |
18 | Holliger, P. and G. Winter (1997) Diabodies: small bis-pecific antibody fragments. Cancer Immunol. Immunother. 45: 128-130 DOI |
19 | Lau, J., C. Tran, P. Licari, and J. Galazzo (2004) Development of a high cell-density fed-batch bioprocess for the heterologous production of 6-deoxyerythronolide B in Escherichia coli. J. Biotechnol. 110: 95-103 DOI ScienceOn |
20 | Wu, J., J. A. Longmate, G. Adamus, P. A. Hargrave, and E. K. Wakeland (1996) Interval mapping of quantitative trait loci controlling humoral immunity to exogenous antigens: evidence that non-MHC immune response genes may also influence susceptibility to autoimmunity. J. Immunol. 157: 2498-2505 |
21 | Yee, L. and H. W. Blanch (1992) Recombinant protein expression in high cell density fed-batch cultures of Escherichia coli. Biotechnology 10: 1550-1556 DOI |
22 | Dixon, A. R., M. R. Price, C. W. Hand, P. E. Sibley, C. Selby, and R. W. Blarney (1993) Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3. Br. J. Cancer 68: 947-949 DOI ScienceOn |
23 | Vyas, V. V., S. Gupta, and P. Sharma (1994) Stability of a recombinant shuttle plasmid in Bacillus subtilis and Es-cherichia coli. Enzyme Microb. Technol. 16: 240-246 DOI ScienceOn |